Tagomics Partners with Agilent Technologies to Revolutionize Multiomic Biomarker Discovery

Bio-Techne Partners with Leader Life Sciences to Expand in the GCC Region

Owkin and Proscia Partner to Revolutionize MSI Testing for Colorectal Cancer with AI-Powered Solutions

Telix Expands Theranostic Pipeline with FAP-Targeting Radiopharmaceuticals

Alamar Biosciences and The Michael J. Fox Foundation Partner to Advance Parkinson’s Disease Biomarker Discovery

Stilla Technologies Partners with Source BioScience to Advance Genomics in the UK and Ireland

Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Foundation Medicine Receives FDA Approval for FoundationOne®Liquid CDx as a Companion Diagnostic for TEPMETKO® in NSCLC

Exact Sciences Partners with Carlos Ponce to Boost Colorectal Cancer Awareness in the Hispanic Community

Merck Receives Positive CHMP Opinion for KEYTRUDA® in Combination Therapy for First-Line Treatment of Non-Epithelioid Mesothelioma

Australia Launches Genomics Australia to Lead Advances in Genomic Medicine

Sidra Medicine Unveils Masterclasses Ahead of PMFG 2024 Summit

FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

Home
/
update
/
details

Telix Expands Theranostic Pipeline with FAP-Targeting Radiopharmaceuticals

NextEdge Admin

20 Nov 2024

2 min 13 sec

Telix Pharmaceuticals has announced plans to expand its theranostic pipeline with new assets targeting Fibroblast Activation Protein (FAP), a promising pan-cancer marker in nuclear medicine. Initially focusing on bladder cancer, this initiative complements Telix’s urology franchise, which includes advanced programs for kidney and prostate cancers.

FAP, expressed in the tumour microenvironment of epithelial cancers and certain cancer types like sarcomas and mesotheliomas, is a compelling target for precision medicine. Telix has secured exclusive global rights to a suite of FAP-targeting radiopharmaceutical candidates through agreements with Professor Frank Roesch and collaborators at Johannes Gutenberg-Universität Mainz, Germany. These next-generation therapeutic assets feature a novel structure enhancing tumour retention while minimizing off-target effects, addressing limitations of earlier compounds. Clinically validated in over 500 patients across various solid tumours, these assets are backed by extensive peer-reviewed research.

Richard Valeix, CEO of Telix, emphasized the significance of partnering with Professor Roesch’s team, citing the assets’ de-risked status, demonstrated safety, and efficacy. Telix aims to advance these candidates for bladder cancer treatment while exploring FAP's broader potential as a pan-cancer target, enriching its development pipeline.

Professor Roesch highlighted the extensive evaluation of FAP inhibitor-based theranostic candidates and acknowledged global collaboration in advancing the molecules. He expressed enthusiasm for Telix’s leadership in radiopharmaceutical innovation, aiming to improve diagnostic precision and therapeutic outcomes for cancer patients through regulatory approval and commercialization.